期刊文献+

嵌合泛素连接酶TrCP-CC及其突变体△F-CC重组腺病毒的构建及鉴定 被引量:1

Construction and Identification of Recombinant Adenoviruses Expressing Chimeric Ubiquitin-ligase TrCP-CC and Its Mutant △F-CC
原文传递
导出
摘要 目的构建嵌合泛素连接酶TrCP-CC及其突变体△F-CC的重组腺病毒,并检测其表达。方法采用PCR和重叠PCR法构建真核表达质粒Migr1-TrCP-CC-HA和Migr1-△F-CC-HA,以此为模板,通过PCR将其克隆至穿梭质粒pAd-Track-CMV,构建重组腺病毒穿梭质粒pAdTrack-TrCP-CC和pAdTrack-△F-CC,再与骨架载体pAdeasy-1经同源重组得到重组腺病毒质粒pAd-TrCP-CC和pAd-△F-CC,转染HEK293细胞进行包装扩增,得到重组腺病毒Ad-TrCP-CC和Ad-△F-CC,测定其滴度,并经RT-PCR检测目的基因的转录水平。结果经酶切和测序证实重组腺病毒质粒pAd-TrCP-CC和pAd-△F-CC构建正确,经HEK293细胞包装后显微镜下可观察到绿色荧光,病毒滴度分别为2.5×109和1.0×109pfu/L,经RT-PCR检测目的基因可有效表达。结论已成功构建重组腺病毒Ad-TrCP-CC和Ad-△F-CC,并在HEK293细胞中成功表达,为进一步研究其靶向融合蛋白Bcr-Abl泛素化和降解的机制奠定了基础。 Objective To construct a recombinant adenovirus expressing chimeric ubiquitin-ligase TrCP-CC and its mutant △F-CC and determine the expressed products.Methods Eukaryotic expression vectors Migr1-TrCP-CC-HA and Migr1-△F-CC-HA were constructed by PCR and overlap PCR,and used as templates for amplification by PCR.The amplified target gene fragments were cloned into shuttle plasmid pAd-Track-CMV,and the constructed recombinant plasmids pAdTrack-TrCP-CC and pAdTrack-△F-CC were used for homologous recombination with skeleton vector pAdeasy-1.The obtained recombinant adenovirus vectors pAd-TrCP-CC and pAd-△F-CC were transfected to HEK293 cells for package and amplification.The obtained recombinant adenoviruses Ad-TrCPCC and Ad-△F-CC were determined for titers,in which the transcription levels of target genes were determined by RT-PCR.Results Both restriction analysis and sequencing proved that recombinant adenovirus vectors pAd-TrCP-CC and pAd-△F-CC were constructed correctly.Green fluorescence was observed in the HEK293 cells transfected with the recombinant adenovirus vectors.Recombinant adenoviruses Ad-TrCP-CC and Ad--△F-CC reached titers of 2.5 × 109 and 1.0 × 109 pfu /L respectively,in which target genes were expressed effectively as proved by RT-PCR.Conclusion Recombinant adenoviruses Ad-TrCP-CC and Ad-△F-CC were successfully constructed and expressed in HEK293 cells,which laid a foundation of study on the mechanism of targeting fusion protein Bcr-Ab1 for ubiquitination and degradation.
出处 《中国生物制品学杂志》 CAS CSCD 2010年第6期561-565,共5页 Chinese Journal of Biologicals
基金 国家自然科学基金(30670901)
关键词 β-TrCP 突变 腺病毒科 泛素蛋白连接酶类 β-TrCP Mutation Adenoviridae Ubiquitin protein ligases
  • 相关文献

参考文献14

  • 1Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia [J]. Lancet, 2007, 370 (9584): 342-350.
  • 2Kantarjian HM, Talpaz M, Giles F, et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance [J]. Ann Intern Med, 2006, 145 (12): 913-923.
  • 3Jariel-Encontre I, Bossis G; Piechaczyk M. Ubiquitin-independent degradation of proteins by the proteasome [J]. Biochim Biophys Acta, 2008, 1786(2): 153-177.
  • 4蔡军,林国生,江洪,王腾,曾彬,罗浩,郭军,李俊,汪蕾.人HCN4基因重组腺病毒载体的构建和鉴定[J].第四军医大学学报,2005,26(20):1861-1864. 被引量:4
  • 5Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer [J]. J Clin Oncol, 2005, 23 (21): 4776-4789.
  • 6Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome [J]. Anuu Rev Biochem, 2009, 78: 477- 513.
  • 7Rodriguez-Gonzalez A, Cyrus K, Salcius M, et al. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer [J]. Oncogene, 2008, 27 (57): 7201-7211.
  • 8Li X, Shen L, Zhang J, et al. Degradation of HER2 by Cbl-based chimeric ubiquitin ligases [J]. Cancer Res, 2007, 67 (18): 8716- 8724.
  • 9Hatakeyama S, Watanabe M, Fujii Y, et al. Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation [J]. Cancer Res, 2005, 65 (17): 7874- 7879.
  • 10Hunter T. Treatment for chronic myelogenous leukemia: the long road to imatinib [J]. Clin Invest, 2007, 117 (8): 2036-2043.

二级参考文献13

  • 1蔡军,林国生,江洪.窦房结起搏细胞膜离子流与4期自动除极[J].中国心脏起搏与心电生理杂志,2004,18(4):304-306. 被引量:5
  • 2蔡军,林国生,江洪,杨波,蒋学俊,王腾,范国华,余奇劲.同种异体心肌细胞移植治疗缓慢性心律失常的实验研究[J].中国心脏起搏与心电生理杂志,2005,19(4):280-283. 被引量:7
  • 3Cornetta K, Morgan RA, Anderson WF. Safety issues related to retroviral-mediated gene transfer in humans. Hum Gene Ther, 1991, 2(1): 5-14.
  • 4Marshall E. Viral threat to newborns under radar. Science, 2002, 295(5560): 1631.
  • 5Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med, 2003, 349 ( 15): 1451-1464.
  • 6Zhao X, Ghaffari S, Lodish H, et al. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Structural Biol, 2002, 9 (2): 117 -120.
  • 7Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Molecular cell, 2003, 12( 1 ): 27-37.
  • 8Chauhan A, Tikoo A, Kapur AK, et al. The taming of the cell penetrating domain of the HIV Tat: Myths and realities. J Control Release, 2007, 117(2): 148-162.
  • 9Kim D, Jeon C, Kim JH, et al. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo. Exp Cell Res, 2006, 312 (8): 1277- 1288.
  • 10Guo XY, Cuillerot JM, Wang T, et al. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene, 1998, 17(7): 825-833.

共引文献6

同被引文献13

  • 1O'Shea J J, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat patllway [J ]. Cell, 2002, 109 (Suppl): S121-S131.
  • 2Reardon C, McKay DM. TGF-beta suppresses IFN-gamma-STAT1- dependent gene transcription by enhancing STAT1-PIAS1 interac- tions in epithelia but not monocytes/macrophages [J ]. J Immunol, 2007, 178 (7) : 4284-4295.
  • 3Rytinki MM, Kaikkonen S, Pehkonen P, et al. PIAS proteins: pleiotropic interactors associated with SUMO [J]. Cell Mol Life Sci, 2009, 66 ( 18): 3029-3041.
  • 4Lee JH, Park SM, Kim OS, et al. Differentia/ SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflam- matory signaling in IFN-gamma-stimulated brain astrocytes [J]. Mol Cell. 2009. 35 (6): 806-817.
  • 5Jennewein C, Kuhn AM, Schmidt MV, et al. Sumoylation of per- oxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cy- tokines [J]. J Immunol, 2008, 181 (8): 5646-5652.
  • 6Munarriz E, Barearoli D, Stephanou A, et al. PIAS-1 is a check- point regulator which affects exit from G1 and G2 by sumoylation of p73 [J]. Mol Cell Biol, 2004, 24 (24): 10593-10610.
  • 7Liu B, Yang R, Wong KA, et al. Negative regulation of NF-kap- paB signaling by PIAS1 [J]. Mol Cell Biol, 2005, 25 (3): 1113- 1123.
  • 8Okubo S, Hara F, Tsuchida Y, et al. NMR structure of the N-ter- minal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers [J], J Biol Chem, 2004, 279 (30): 31455-31461.
  • 9Coppola D, Parikh V, Boulware D, et al. Substantially reduced expression of PIAS1 is associated with colon cancer development [J]. J Cancer Res Clin Oncol, 2009, 135 (9): 1287-1291.
  • 10Yotnda P, Onishi H, Heslop HE, et al. Efficient infection of primitive hematopoietie stem cells by modified adenovirus [J]. Gene Ther, 2001, 8 (12): 930-937.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部